Skip to content
Menu

Purple Biotech Ltd PPBT

Full chart Compare
Set alert

Price alert · PPBT

All alert types
1.53 USD -0.07 (-4.09%)

Regular-session close

1.50 -0.02 -1.63%

After hours · Nov 20, 4:21 PM ET

1.29 Day range 1.56
0.924 52-week range 8.74
YTD
-76.82%
1 year
-79.99%

5D +0.30 (+21.28%)

1.401.60ThuFriMonTueWed1.71
Market cap
2.48M
EPS (ttm)
-47.64
Shares out
2.58M
Forward P/E
-1.69
YTD return
-76.82%
1-year return
-79.99%
50-day average
3.64
200-day average
8.21
Volume
21.78K
Avg volume
1.26M
Open
1.50
Previous close
1.59
Day's range
1.29 – 1.56
52-week range
0.924 – 8.74
Beta
0.38
Price target
33.00 (+2063.9%)

Key statistics

Enterprise value
695.00M
Price / book
27.21
Free cash flow
-8.88M
Total cash
7.39M
Total debt
261.00K
Return on equity
-44.67%
Short % of float
1.33%

Fundamental scorecard

10 of 25 checks passed on PPBT’s reported financials

ValueGrowthProfitabilityHealthDividend

10of 25 checks passed

  • Value 3 of 5
  • Growth 0 of 5
  • Profitability 3 of 5
  • Financial health 4 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
PPBT Revenue — quarterly 0
PPBT Net income — quarterly 981.00K
PPBT EPS — quarterly -0.60

Earnings

PPBT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 15, 2024Sep 1, 2024-1.20-1.37-0.17-14.17%
Aug 16, 2024Jun 1, 2024-2.60-1.60+1.00+38.46%
May 21, 2024Mar 1, 2024-3.00-3.000.000.00%
Mar 5, 2024Dec 1, 2023-3.40-6.40-3.00-88.24%
Nov 21, 2023Sep 1, 2023-4.40-4.20+0.20+4.55%
Aug 22, 2023Jun 1, 2023-5.00-4.60+0.40+8.00%

Upgrades / downgrades

PPBT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024HC Wainwright & Co.reitBuyBuy
Sep 20, 2024HC Wainwright & Co.mainBuyBuy
Aug 19, 2024HC Wainwright & Co.mainBuyBuy
Jul 11, 2024HC Wainwright & Co.reitBuyBuy
May 21, 2024HC Wainwright & Co.reitBuyBuy
Apr 26, 2024HC Wainwright & Co.reitBuyBuy

About Purple Biotech Ltd

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel

News

Your note

Sign in to keep a note on PPBT — it syncs with the Stock Master app.

Institution ownership

PPBT institution ownership
Holder% heldSharesValueReported
Armistice Capital, LLC12.10%158,000584.60KSep 29, 2024
Morgan Stanley0.62%8,05529.80KSep 29, 2024
BNP Paribas Financial Markets0.28%3,67513.60KSep 29, 2024
Td Waterhouse Canada Inc. 0.02%200740Sep 29, 2024
Tower Research Capital LLC (TRC)0.02%254939Sep 29, 2024
Royal Bank of Canada0.01%107395Sep 29, 2024

Fund ownership

PPBT fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.05%6332.34KOct 30, 2024